Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Teml A, Schaeffeler E, Schwab M, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR; International AZT-2 Study Group. Reinisch W, et al. Among authors: lukas m. Gut. 2010 Jun;59(6):752-9. doi: 10.1136/gut.2009.194159. Gut. 2010. PMID: 20551460 Clinical Trial.
Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis.
Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horynski M, Bátovský M, Lozynsky YS, Zakharash Y, Rácz I, Kull K, Vcev A, Faszczyk M, Dilger K, Greinwald R, Mueller R; International Salofalk OD Study Group. Kruis W, et al. Aliment Pharmacol Ther. 2011 Feb;33(3):313-22. doi: 10.1111/j.1365-2036.2010.04537.x. Epub 2010 Dec 8. Aliment Pharmacol Ther. 2011. PMID: 21138455 Clinical Trial.
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Gross V, Bunganic I, Belousova EA, Mikhailova TL, Kupcinskas L, Kiudelis G, Tulassay Z, Gabalec L, Dorofeyev AE, Derova J, Dilger K, Greinwald R, Mueller R; International BUC-57 Study Group. Gross V, et al. J Crohns Colitis. 2011 Apr;5(2):129-38. doi: 10.1016/j.crohns.2010.11.006. Epub 2010 Dec 14. J Crohns Colitis. 2011. PMID: 21453882 Clinical Trial.
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17. Lancet. 2025. PMID: 39706209 Clinical Trial.
Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre Study.
Farkas B, Bessissow T, Limdi JK, Sethi-Arora K, Kagramanova A, Knyazev O, Bezzio C, Armuzzi A, Lukas M, Michalopoulos G, Chaskova E, Savarino EV, Castiglione F, Rispo A, Schäfer E, Saibeni S, Filip R, Attauabi M, Fousekis FS, Bacsur P, Resál T, Bálint A, Ivány E, Szepes Z, Bősze Z, Fábián A, Bor R, Farkas K, Lakatos PL, Molnár T. Farkas B, et al. Among authors: lukas m. J Clin Med. 2024 Dec 20;13(24):7804. doi: 10.3390/jcm13247804. J Clin Med. 2024. PMID: 39768726 Free PMC article.
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Lancet. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8. Epub 2024 Nov 21. Lancet. 2024. PMID: 39581202 Clinical Trial.
Structured magnetic resonance imaging and endoanal ultrasound anal fistulas reporting template (SMART): An interdisciplinary Delphi consensus.
Sudoł-Szopińska I, Garg P, Mellgren A, Spinelli A, Breukink S, Iacobellis F, Kołodziejczak M, Ciesielski P, Jenssen C; SMART Collaborative Group; Santoro GA. Sudoł-Szopińska I, et al. World J Gastrointest Surg. 2024 Oct 27;16(10):3288-3300. doi: 10.4240/wjgs.v16.i10.3288. World J Gastrointest Surg. 2024. PMID: 39575264 Free PMC article.
Post-Discharge Outcomes of Elderly Patients Hospitalized for Inflammatory Bowel Disease Flare Complicated by Clostridioides difficile Infection.
Goren I, Fallek Boldes O, Boldes T, Knyazev O, Kagramanova A, Limdi JK, Liu E, Sethi-Arora K, Holvoet T, Eder P, Bezzio C, Saibeni S, Vernero M, Alimenti E, Chaparro M, Gisbert JP, Orfanoudaki E, Koutroubakis IE, Pugliese D, Cuccia G, Calviño Suarez C, Ribaldone DG, Veisman I, Sharif K, Aratari A, Papi C, Mylonas I, Mantzaris GJ, Truyens M, Lobaton T, Nancey S, Castiglione F, Nardone OM, Calabrese G, Karmiris K, Velegraki M, Theodoropoulou A, Shitrit AB, Lukas M, Vojtechová G, Ellul P, Bugeja L, Savarino EV, Fischler TS, Dotan I, Yanai H. Goren I, et al. Among authors: lukas m. J Crohns Colitis. 2024 Oct 21:jjae161. doi: 10.1093/ecco-jcc/jjae161. Online ahead of print. J Crohns Colitis. 2024. PMID: 39435855
Recruitment of emergency department patients to a prospective observational study.
Shubeck C, Reyes Garay H, Nelson BP, Wilder M, Degtyar A, Lukas M, Gordon L, Loo GT, Coleman B, Richardson LD, Souffront K. Shubeck C, et al. Among authors: lukas m. Int J Emerg Med. 2024 Oct 7;17(1):142. doi: 10.1186/s12245-024-00717-y. Int J Emerg Med. 2024. PMID: 39375594 Free PMC article.
373 results